Ado-Trastuzumab Emtansine (Kadcyla)

Updated 
August 31, 2015
Reviewed By: 

Ado-trastuzumabinfo-icon emtansine (Kadcyla) is the targeted therapyinfo-icon trastuzumab (Herceptin) with the chemotherapy medicineinfo-icon emtansine attached. It may also be called T-DM1.

Ado-trastuzumab emtansine is an antibody-drug conjugate, a treatment that pairs a chemotherapyinfo-icon medicine with a targeted therapy. The trastuzumab helps deliver the chemotherapy directly to the tumorinfo-icon cells. This helps limit the side effects of the chemotherapy on the healthy cells.

How Ado-Trastuzumab Emtansine Works

Trastuzumabinfo-icon attaches to the HER2 proteininfo-icon, allowing the chemotherapyinfo-icon emtansine to enter the cancer cellinfo-icon. Once inside the cell, the emtansine becomes active and kills the cell. This way, ado-trastuzumab emtansine causes cancer cells to die, while leaving healthy cells unharmed.

How Ado-Trastuzumab Emtansine Is Given

Ado-trastuzumabinfo-icon emtansine is given by veininfo-icon once every 3 weeks for as long as it controls the cancer, or severe side effects develop.

Side Effects and Things to Remember

Common side effects of ado-trastuzumabinfo-icon emtansine include

Some people who take ado-trastuzumab emtansine develop a low white blood count, which may put you at risk for infectioninfo-icon. Call your doctor right away if you show any symptoms of infection, such as a fever with chills.

If you have serious side effects, your doctor may stop treatment for a time or switch you to another treatment.

Before starting ado-trastuzumab emtansine, tell your doctor about any history of heart or lung problems as well as any medicines you are taking, including vitamins, herbal supplements and over-the-counterinfo-icon medicines. You should not become pregnant while taking ado-trastuzumab emtansine.

Your doctor, pharmacistinfo-icon or nurseinfo-icon can help you manage your side effects. You can also go to our section on Side Effects for more information.

You must have Javascript enabled to use this form.

More In Targeted Therapy

Article December 27, 2017